$RLMD

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

CORAL GABLES, Fla., Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- Relmada Therapeutics, Inc. ( Nasdaq: RLMD, "Relmada" or the "Company" ) , a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced the pricing of its ...

Original reporting
GlobeNewswire · Relmada Therapeutics
Published Nov 4, 2025, 12:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 4, 2025, 1:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants — source image
Decision brief

The 30-second read

$RLMDNeutralMed
01

Why it matters

The announcement is likely to bolster investor confidence temporarily, but long-term effects depend on clinical trial outcomes and market conditions.

02

Market read

The news is relevant for biotech investors and traders focusing on clinical-stage companies, with moderate immediate impact expected.

03

What to watch

Market reaction may be muted if investors have already priced in the funding or if broader market conditions are unfavorable.

Timing: Immediate, as the news is recent and may influence trading today.

Background

Relmada Therapeutics is a clinical-stage biotech company focusing on CNS and oncology therapies. The recent funding aims to support ongoing clinical trials and development programs.

Company-level read

Ticker impact

$RLMDNeutralMedium confidence
Context

Relmada Therapeutics' recent funding event may influence its stock price and investor sentiment.

Expected impact

Moderate upward movement expected in the short term, potential stabilization or slight decline if dilution concerns dominate.

Evidence & confidence

Funding announcements typically signal financial strength, but dilution effects and market perception can moderate the impact.

Market effects

Potential positive sentiment in biotech and life sciences sectors due to increased funding activity.

Limited regional impact; primarily affects US-based biotech investors.

Minimal global market impact, as the news pertains to a specific company's funding event.

Counterpoint

The funding could lead to dilution and potential negative long-term effects, so some traders might consider shorting or reducing exposure.

Key entities

  • Relmada Therapeutics

    A biotech company specializing in CNS and oncology therapies.

Related articles

$RLMDMed

RELMADA THERAPEUTICS, INC. (RLMD): Results of Operations and Financial Condition

RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030099301ex99-1.htm PRESS RELEASE DATED AUGUST 6, 2026, REGARDING A CORPORATE UPDATE AND REPORTING ITS FINANCIAL RESULTS FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 Exhibit 99.1 Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Busin

$MDTMed

Jury Orders Medtronic to Pay $88 Million After Finding Surgeons Were Not Adequately Warned About a Hernia Mesh

A federal jury ordered Medtronic’s Covidien unit to pay $88 million to Larry and Tammy Patterson after finding surgeons were not adequately warned about risks of Covidien’s Symbotex hernia mesh. The Aug. 4 verdict followed a three-week trial in Massachusetts. Jurors awarded $77 million to Larry and $11 million for loss of consortium, with no punitive damages.

$LMTMedAI 8/10

What is Patriot missile system, why its supplies are down

The article explains the U.S.-made Patriot mobile air defense system and why interceptor missile supplies are down. It cites Raytheon and Lockheed for system details and notes CSIS estimates about 65% of U.S. interceptors were expended Feb to July, leaving under 850. It says the U.S. approved 5,250 interceptors for Gulf states and awarded Lockheed a contract up to $58.6B.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.